Peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC or 177Lu-DOTATATE has demonstrated its efficacy in the treatment of neuroendocrine- and somatostatin-receptor expressing tumours . Several clinical trials have confirmed that adverse effects are represented by possible renal impairment and low but not absent haematological toxicity
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy
Paganelli, GiovanniPenultimo
;
2012
Abstract
Peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC or 177Lu-DOTATATE has demonstrated its efficacy in the treatment of neuroendocrine- and somatostatin-receptor expressing tumours . Several clinical trials have confirmed that adverse effects are represented by possible renal impairment and low but not absent haematological toxicityFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
piccin2011.pdf
accesso aperto
Tipologia:
Full text (versione editoriale)
Licenza:
Creative commons
Dimensione
62.17 kB
Formato
Adobe PDF
|
62.17 kB | Adobe PDF | Visualizza/Apri |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
